656
Views
13
CrossRef citations to date
0
Altmetric
Research Paper

Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells

, , , , &
Pages 1009-1017 | Received 20 Feb 2012, Accepted 04 Jun 2012, Published online: 24 Jul 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Min Li, Hongling Chen, Tong Sun, Zhuo Ma, Xi Chen, Dandan Wu, Wenbin Huang & Xuerong Wang. (2020) p70S6K Promotes Acquired Resistance of Erlotinib Through Induction of Epithelial-Mesenchymal Transition in Non-Small Cell Lung Carcinoma. OncoTargets and Therapy 13, pages 5257-5270.
Read now
Zhongyuan Gao, Ting Yuan, Xiao Zhou, Ping Ni, Geng Sun, Ping Li, Zhixiang Cheng & Xuerong Wang. (2018) Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression. Cancer Biology & Therapy 19:5, pages 407-415.
Read now

Articles from other publishers (11)

Mahmood Araghi, Reza Mannani, Ali Heidarnejad maleki, Adel Hamidi, Samaneh Rostami, Salar Hozhabri Safa, Fatemeh Faramarzi, Sahar Khorasani, Mina Alimohammadi, Safa Tahmasebi & Reza Akhavan-Sigari. (2023) Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell International 23:1.
Crossref
Ting Yuan, Ping Ni, Zuhao Zhang, Dandan Wu, Geng Sun, Haijun Zhang, Baoan Chen, Xuerong Wang & Zhixiang Cheng. (2022) Targeting BET proteins inhibited the growth of non‐small cell lung carcinoma through downregulation of Met expression. Cell Biology International 47:3, pages 622-633.
Crossref
Yuting Meng, Xixi Qian, Li Zhao, Nan Li, Shengjie Wu, Baoan Chen, Tong Sun & Xuerong Wang. (2021) Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma. Cancer Cell International 21:1.
Crossref
Yong Lin, Qiangye Gu, Zongwen Sun, Baowei Sheng, Congcong Qi, Bing Liu, Tian Fu, Cun Liu & Yan Zhang. (2017) Upregulation of miR-3607 promotes lung adenocarcinoma proliferation by suppressing APC expression. Biomedicine & Pharmacotherapy 95, pages 497-503.
Crossref
Marion Le Grand, Raphael Berges, Eddy Pasquier, Marie-Pierre Montero, Laurence Borge, Alice Carrier, Sophie Vasseur, Veronique Bourgarel, Duje Buric, Nicolas André, Diane Braguer & Manon Carré. (2017) Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression. Scientific Reports 7:1.
Crossref
Dandan Wu, Jie Cheng, Geng Sun, Shengjie Wu, Min Li, Zhongyuan Gao, Sulan Zhai, Ping Li, Dongming Su & Xuerong Wang. (2016) p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma. Oncotarget 7:24, pages 36539-36550.
Crossref
Zhenguo Sun, Zhou Wang, Xiangyan Liu & Dong Wang. (2015) New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Anti-Cancer Drugs 26:1, pages 1-14.
Crossref
Aneliya Kostadinova, Tanya Topouzova-Hristova, Albena Momchilova, Rumiana Tzoneva & Martin R. Berger. 2015. 27 66 .
Haitao Meng, Yingming Jin, Hui Liu, Liangshun You, Chunmei Yang, Xue Yang & Wenbin Qian. (2013) SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt. Journal of Hematology & Oncology 6:1.
Crossref
SONG LIANG, RENHUA GUO, ZHIHONG ZHANG, DONGXIAO LIU, HAO XU, ZEKUAN XU, XUERONG WANG & LI YANG. (2013) Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth. Oncology Reports 29:6, pages 2422-2430.
Crossref
Wim J. van Blitterswijk & Marcel Verheij. (2013) Anticancer mechanisms and clinical application of alkylphospholipids. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1831:3, pages 663-674.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.